tiprankstipranks
Balaji Amines Limited (IN:BALAMINES)
:BALAMINES
India Market
Want to see IN:BALAMINES full AI Analyst Report?

Balaji Amines Limited (BALAMINES) AI Stock Analysis

5 Followers

Top Page

IN:BALAMINES

Balaji Amines Limited

(BALAMINES)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 5.2)
Rating:63Neutral
Price Target:
₹2,148.00
▲(96.92% Upside)
Action:Reiterated
Date:06/03/26
The score is driven by a strong balance sheet and favorable technical momentum, offset by weak FY2026 free-cash-flow performance and a demanding valuation (high P/E with a low dividend yield).
Positive Factors
Low Leverage / Strong Balance Sheet
Very low debt-to-equity (~0.07) and a large equity base provide durable financial flexibility. This reduces refinancing and interest-rate risk, supports capacity expansion or cyclical downturns without stressing credit, and preserves optionality for strategic investments over months.
Negative Factors
Negative Free Cash Flow
Materially negative FCF in FY2026 signals heavier reinvestment or working-capital strain and weak cash conversion. Sustained negative FCF can constrain capital returns, force external financing, or delay deleveraging, raising medium-term funding and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Very low debt-to-equity (~0.07) and a large equity base provide durable financial flexibility. This reduces refinancing and interest-rate risk, supports capacity expansion or cyclical downturns without stressing credit, and preserves optionality for strategic investments over months.
Read all positive factors

Balaji Amines Limited (BALAMINES) vs. iShares MSCI India ETF (INDA)

Balaji Amines Limited Business Overview & Revenue Model

Company Description
Balaji Amines Limited, an Indian company, specializes in the production and global distribution of methylamines, ethylamines, their associated derivatives, alongside a diverse portfolio of specialty chemicals and pharmaceutical excipients. The fir...
How the Company Makes Money
Balaji Amines makes money primarily by manufacturing and selling amines and amine-based chemical derivatives/intermediates to industrial customers. Its core revenue model is B2B product sales: it produces bulk and specialty amines (and related der...

Balaji Amines Limited Financial Statement Overview

Summary
Profitability is solid but below prior peak years, with FY2026 gross margin ~34% and net margin ~11.7% alongside only modest revenue growth (~4.4%). The balance sheet is strong with very low leverage (FY2026 debt-to-equity ~0.07), but cash-flow quality is a key risk as FY2026 free cash flow turned materially negative (~-1.74B) and cash conversion weakened.
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
45
Neutral
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue13.64B14.25B13.97B16.08B23.38B23.20B
Gross Profit5.56B4.88B4.88B3.50B8.39B8.57B
EBITDA2.52B2.65B2.65B3.53B6.24B6.36B
Net Income1.46B1.67B1.58B2.05B3.26B3.68B
Balance Sheet
Total Assets23.31B27.43B22.52B21.46B19.63B18.75B
Cash, Cash Equivalents and Short-Term Investments1.86B2.71B3.50B3.31B3.09B515.37M
Total Debt314.46M1.33B110.27M196.97M575.74M1.01B
Total Liabilities2.75B5.91B2.34B2.53B2.65B5.60B
Stockholders Equity18.82B19.76B18.45B17.22B15.54B12.50B
Cash Flow
Free Cash Flow-1.62B-1.74B874.82M704.14M2.62B842.07M
Operating Cash Flow222.05M1.96B2.73B3.34B3.82B2.32B
Investing Cash Flow-1.15B-3.58B-1.61B-1.64B-1.86B-1.47B
Financing Cash Flow-169.00M865.75M-447.73M-749.66M-812.33M-565.13M

Balaji Amines Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1090.80
Price Trends
50DMA
1610.32
Positive
100DMA
1347.79
Positive
200DMA
1325.05
Positive
Market Momentum
MACD
158.15
Positive
RSI
66.41
Neutral
STOCH
55.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAMINES, the sentiment is Positive. The current price of 1090.8 is below the 20-day moving average (MA) of 2014.03, below the 50-day MA of 1610.32, and below the 200-day MA of 1325.05, indicating a bullish trend. The MACD of 158.15 indicates Positive momentum. The RSI at 66.41 is Neutral, neither overbought nor oversold. The STOCH value of 55.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BALAMINES.

Balaji Amines Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
₹91.72B50.900.62%-2.29%-3.26%
64
Neutral
₹29.55B19.810.09%15.19%9.27%
63
Neutral
₹71.53B41.600.97%2.00%6.14%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
57
Neutral
₹146.40B86.060.06%64.44%77.60%
52
Neutral
₹7.64B141.041.07%-14.55%-74.70%
52
Neutral
₹50.92B177.200.09%10.86%-17.60%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:BALAMINES
Balaji Amines Limited
2,137.35
757.63
54.91%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,843.75
-215.26
-10.45%
IN:ANURAS
Anupam Rasayan India Ltd.
1,279.50
150.84
13.36%
IN:FAIRCHEMOR
Fairchem Organics Ltd
609.85
-334.72
-35.44%
IN:NEOGEN
Neogen Chemicals Ltd.
1,930.75
336.92
21.14%
IN:ROSSARI
Rossari Biotech Ltd
560.25
-109.90
-16.40%

Balaji Amines Limited Corporate Events

Balaji Amines launches shareholder campaign on KYC and demat window
May 9, 2026
Balaji Amines Limited announced that it has published newspaper advertisements in The Indian Express and Pudhari as part of the second 100 days ‘Saksham Niveshak’ campaign, aimed at promoting KYC updates and other shareholder-related i...
Balaji Amines Opens Special Window for Transfer and Demat of Physical Shares
Mar 5, 2026
Balaji Amines Limited has announced that it has published newspaper advertisements in The Indian Express and Lokmat regarding a special window for the transfer and dematerialisation of physical shares. The move reflects the company’s ongoing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 03, 2026